High-dose chemotherapy using melphalan (HDMEL) is an important component of many conditioning regimens that are given before autologous hematopoietic stem cell transplantation (AHSCT). In contrast to the situation in myeloma, and to a lesser degree acute leukemia, only a very limited published experience exists with the use of HDMEL conditioning as a single agent in doses requiring AHSCT for lymphoma, both Hodgkin lymphoma (HL) and especially non-Hodgkin lymphoma (NHL). Thus, we report results of treating 26 lymphoma patients (22 with NHL and four with HL) with HDMEL 220-300 mg/m 2 plus amifostine (AF) cytoprotection and AHSCT as part of a phase I-II trial. Median age was 51 years (range 24-62 years); NHL histology was varied, but was aggressive (including transformed from indolent) in 19 patients, indolent in two patients and mantle cell in one. All 26 patients had been extensively treated; 11 were refractory to the immediate prior therapy on protocol entry and two had undergone prior AHSCT. All were deemed ineligible for other, 'first-line' AHSCT regimens. Of these 26 patients, 22 survived to initial tumor evaluation on D þ 100. At this time, 13 were in complete remission, including four patients who were in second CR before HDMEL þ AF þ AHSCT. Responses occurred at all HDMEL doses. Currently, seven patients are alive, including five without progression, with a median followup in these latter patients of D þ 1163 (range D þ 824 to D þ 1630); one of these patients had a nonmyeloablative allograft as consolidation on D þ 106. Conversely, 14 patients relapsed or progressed, including five who had previously achieved CR with the AHSCT procedure.
High-dose chemotherapy using melphalan (HDMEL) is an important component of many conditioning regimens that are given before autologous hematopoietic stem cell transplantation (AHSCT). In contrast to the situation in myeloma, and to a lesser degree acute leukemia, only a very limited published experience exists with the use of HDMEL conditioning as a single agent in doses requiring AHSCT for lymphoma, both Hodgkin lymphoma (HL) and especially non-Hodgkin lymphoma (NHL). Thus, we report results of treating 26 lymphoma patients (22 with NHL and four with HL) with HDMEL 220-300 mg/m 2 plus amifostine (AF) cytoprotection and AHSCT as part of a phase I-II trial. Median age was 51 years (range 24-62 years); NHL histology was varied, but was aggressive (including transformed from indolent) in 19 patients, indolent in two patients and mantle cell in one. All 26 patients had been extensively treated; 11 were refractory to the immediate prior therapy on protocol entry and two had undergone prior AHSCT. All were deemed ineligible for other, 'first-line' AHSCT regimens. Of these 26 patients, 22 survived to initial tumor evaluation on D þ 100. At this time, 13 were in complete remission, including four patients who were in second CR before HDMEL þ AF þ AHSCT. Responses occurred at all HDMEL doses. Currently, seven patients are alive, including five without progression, with a median followup in these latter patients of D þ 1163 (range D þ 824 to D þ 1630); one of these patients had a nonmyeloablative allograft as consolidation on D þ 106. Conversely, 14 patients relapsed or progressed, including five who had previously achieved CR with the AHSCT procedure.
Two patients, both with HL, remain alive after progression; one is in CR following salvage radiotherapy. Six patients died due to nonrelapse causes, including two NHL patients who died while in CR. We conclude that HDMEL þ AF þ AHSCT has significant single-agent activity in relapsed or refractory NHL and HL. This experience may be used as a starting point for subsequent dose escalation of HDMEL (probably with AF) in established combination regimens. For non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) patients who are not treated successfully with conventional therapy, high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (AHSCT) has proven curative in a substantial number of cases, and is the standard of care in some situations. 1 That said, many of the elements of HDC þ AHSCT are not standardized; [1] [2] [3] [4] [5] specifically, no one HDC regimen has been proven optimal. [1] [2] [3] [4] [5] [6] [7] [8] Nonetheless, carmustine (BCNU), etoposide (VP16-213), cytarabine (Ara-C) and melphalan (MEL) -the so-called BEAM regimen 9 -is widely utilized, and had no obvious superior in recent large but nonrandomized analyses. 7, 8 However, and admittedly minimizing the uncertain role of cotransplantation of clonogenic lymphoma cells, 10, 11 BEAM permits a substantial number of relapses, and increasing the activity of BEAM (or other regimens) without excessive toxicity could be very useful. One such approach involves intensification of the intrinsic agents in an established regimen such as BEAM.
Probably due to its capacity for extensive myelosuppression, the use of MEL at conventional dose is now fairly uncommon. 12 However, and while the relative antineoplastic 'contribution' of the individual agents in most regimens is unknown, the fact that HDC using melphalan (HDMEL) is the only agent dose escalated to near-maximal levels 9, 12 in BEAM indicates confidence in its potency.
When utilized in doses X200 mg/m 2 , MEL is associated with severe regimen-related toxicity (RRT), [13] [14] [15] mainly confined to the gastrointestinal mucosa. Owing to this observation, plus the likelihood of increased toxicity with higher doses, there has been little published experience using MEL doses X200 mg/m 2 , with doses of 220-225 mg/m 2 being utilized in autologous 13, 14 and 240 mg/m 2 in the allogeneic 15 transplant experience. Amifostine (AF) is a thiol prodrug that has shown the ability to protect against MEL toxicity to a number of organs, including the mucosa, in both preclinical rodent models 16 as well as certain studies in humans. 17 MEL has pharmacokinetic features 12 that match well with those of AF 18 and the presumed requirement for the active intracellular moiety, WR-1065. 19 In addition, MEL has a wide spectrum of antitumor activity against a variety of hematologic and nonhematologic neoplasms. 12 Moreover, there is little (if any) information that AF may be protective against lymphoma cells, as indicated mainly by preclinical studies. 20 We have recently completed a phase I study 21 using AF to permit the use of escalated doses of HDMEL beyond those usually utilized in the AHSCT setting in 58 patients with a variety of malignant diagnoses. In this experience, HDMEL was escalated from the putative maximum tolerable dose (MTD) without AF of 220 ng/m 2 in 20 mg/m 2 increments to 300 mg/m 2 . The presence of two cases of severe RRT at the HDMEL dose of 300 mg/m 2 led to the assessment that 280 mg/m 2 may be the new MTD; none of 27 patients treated at this dose had severe RRT. The doselimiting toxicity (DLT) was not clearly defined; somewhat surprisingly, it was not mucosal, but may have been cardiac given the repeated occurrence of atrial fibrillation. Less likely, the hepatotoxicity may represent the DLT, as one patient treated at HDMEL 300 mg/m 2 died from hepatic necrosis, an uncommon event at lower doses. 12 Although the phase II portion of this study has focused on patients with myeloma, 22 we have also entered NHL and HL patients on this protocol who were not eligible for other 'first-line' HDC/AHSCT regimens. Herein, we report results obtained in 26 lymphoma patients, with NHL and HL, treated during both the phase I and the phase II portions of this trial with HDMEL 220-300 mg/m 2 þ AF þ AHSCT.
Patients and methods

Eligibility criteria
Between June 5, 1998 and July 27, 2000 inclusive, 14 patients with a primary diagnosis of lymphoma who were ineligible for other, higher-priority HDC þ AHSCT studies were entered into a phase I study utilizing HDMEL (220-300 mg/m 2 ); this study was open to patients with other diagnoses, and 44 other patients were so treated, as indicated previously. 21 Subsequently, between the inclusive dates of August 17, 2000 and February 14, 2001 , a further 12 patients were entered in a phase II study utilizing HDMEL 280 mg/m 2 þ AF þ AHSCT for a spectrum of hematologic malignancies, and this report combines patients from both groups for response evaluation. This is considered reasonable, since phase I studies using HDC and AHSCT are not hindered by the potential use of suboptimal doses as in more traditional phase I studies.
The inclusion criteria for both studies included: (1) confirmed diagnosis of a malignant disease treated with HDC/AHSCT; (2) age 18-70 years; (3) satisfactory hematologic and nonhematologic parameters to permit HDC þ AHSCT; (4) absence of, or ineligibity for, a higherpriority intrainstitutional HDC/AHSCT protocol; and (5) informed consent under the auspices of each institution's IRB. The exclusion criteria included: (1) active brain or meningeal involvement; (2) inability to discontinue antihypertensives for 24 h prior to administration of AF; or (3) presence of a comorbid condition which, in the view of the attending physician, rendered the patient at excessive risk from anticipated treatment complications.
Definitions
Whenever possible, histologic diagnoses were standardized to the WHO classification. 23 Disease status, response determinations and RRT were categorized as detailed previously. [24] [25] [26] Hematologic recovery was defined as the first day of continuous ANC X0.5 K/ml and the last day of platelet transfusion. All patients were evaluable for outcome, calculated from the day of AHSCT (D þ 0). Formal response determinations were performed on D þ 100, and patients who died before D þ 100 of complications were considered unevaluable for response, unless obvious progression had occurred.
CD34 þ cell mobilization CD34 þ cell collection, usually obtained by mobilization technique, was left to the discretion of the attending physician. Owing to our anticipation that these heavily treated patients would not mobilize very well, no lower limit of CD34 þ cell number was specified. 27 No grafts underwent ex vivo manipulation to remove potentially contaminating clonogenic lymphoma cells.
HDC treatment regimen
All patients received AF 740 mg/m 2 , with doses calculated to the nearest 10 mg. Two doses of AF were given 24 h apart, following preparation that included the discontinuance of antihypertensives, the use of prophylactic dexamethasone, an antiemetic regimen (usually including a serotonin antagonist and dexamethasone), recumbency, saline volume loading and prophylactic calcium salt administration. Additional AF was given over 15 min with a volumetric pump at three of the participating institutions and over 5 min at another. MEL doses were calculated to the nearest 1.0 mg; doses were prepared immediately prior to administration and delivered directly for administration. No more than 90 min elapsed between the time of MEL vial reconstitution and completion of the infusion.
Post-AHSCT management
In general, institutional policy was utilized for acute management. Areas included were as follows: antiemetics, AHSC reinfusion, hematologic growth factors, prophylactic and therapeutic antibiotics, blood component transfusion, fluid and electrolyte management, nutritional support, etc.
Statistical techniques
Progression-free and overall survival were calculated by the method of Kaplan and Meier. 28 
Results
Clinical characteristics
Key clinical features are outlined in Table 1 . Notable were the diversity of histologies, the heavy exposure history to prior chemotherapeutic regimens and the refractory disease status in 11 patients.
Overall patient outcomes
Between the dates of June 5, 1998 and February 14, 2001 inclusive, a total of 26 lymphoma patients were recruited for this trial from four institutions. Overall outcome results are summarized in Table 2 . All seven of the patients currently alive have been followed for more than 1 year after AHSCT; five patients (three NHL and two HL) are alive and continuously disease-free after AHSCT at D þ 1638, þ 1221, þ 1163, þ 1075 and þ 824.
During the phase I portion of the trial, post-AHSCT therapy was given to two NHL patients in an attempt to prolong or maintain remission. In one, this involved a short course of interferon-alfa; another underwent 'nonmyeloablative ' 
Conversely, 14 patients have progressed and 12 died following progression. Six patients died of nonrelapse causes, including two patients who died during CR post-AHSCT. Causes included fungal pneumonia, secondary myelodysplastic syndrome (MDS), P. carinii pneumonia, CNS hemorrhage, extensive pulmonary hemorrhage due to rapid tumor lysis and hepatic necrosis (one patient died of each cause).
CD34 þ mobilization
As indicated in Table 3 , 13 patients had CD34 þ mobilization with G-CSF alone and an additional 12 received additional chemotherapy (paclitaxel alone in one, etoposide alone in two, cyclophosphamide alone in two, cyclophosphamide and etoposide with or without prednisone in four and high-dose cytarabine with or without other agents in three). One patient underwent steady-state marrow harvest to minimize delay in the initiation of HDMEL due to rapidly progressive NHL. The median CD34 þ cell yield was 4.84 Â 10 6 /kg (range 0.35-63.0). Two NHL patients who underwent multiple attempts to obtain adequate numbers of CD34 þ cells both in the blood and marrow had cumulative CD34 þ yields well under 2.0 Â 10 6 /kg (ie 1.18 and 0.35).
Toxicity AF infusion toxicity. Most patients developed mild, nongraded 24 toxicity temporally related to the AF infusions; in none of these patients were these symptoms or signs judged severe enough to interrupt the AF infusion. Despite the prophylactic administration of calcium salts, two patients developed symptomatic hypocalcemia requiring additional, and occasionally prolonged, calcium salt infusions and/or oral supplements.
Hematologic toxicity and recovery. The development of severe pancytopenia was universal, but hematologic recovery was generally prompt, despite considerable institutional variation in post-AHSCT filgrastim administration. In the 23 patients who recovered neutrophils X0.5 K Â 10 6 /l, the median day of ANC recovery was D þ 12 (range þ 8 to þ 38). In the 21 patients who recovered platelets, freedom from the need for platelet transfusions occurred at median D þ 14 (range þ 8 to þ 342).
Four patients had delayed count recovery defined as failure to recover either ANC or platelets to the levels defined above XD þ 30. In three of these patients, low CD34 þ cell doses or the situation of a second AHSCT were likely etiologic. However, one patient given HDMEL 220 mg/m 2 þ AF þ AHSCT with a CD34 þ yield of 29.0 Â 10 6 /kg experienced delayed hematologic recovery (ANC on D þ 38 and platelets on D þ 33, respectively) without an obvious etiology. No 'late' (ie after initial recovery) impairment of hematologic parameters developed in the absence of obvious factors such as marrow relapse, salvage chemotherapy or radiotherapy, etc.
Regimen-related toxicity. Two patients given HDMEL 220 mg/m 2 had no gradable RRT. Grade I RRT was determined in 15 patients and grade II RRT in eight; in all cases, this RRT was mucosal. One patient had grade IV cardiac RRT (ie refractory atrial fibrillation that resulted in multiorgan failure) and another had grade IV hepatic RRT (ie a clinical picture of veno-occlusive disease with a histology revealing necrosis); both received HDMEL 300 mg/m 2 .
Responses
Of the 22 evaluable patients, nine with measurable disease (excluding those four patients in second CR) entered CR or CRu at D þ 100. Conversely, nine failed to achieve CR/ CRu, including four patients who achieved PR (One patient who achieved PR was given local radiotherapy in an attempt to produce CR; the date of the initiation of radiotherapy is coded as the date of progression.) In these latter patients, the median (range) time to progression was D þ 100 (D þ 0 to D þ 341). Two patients are alive with progression and five patients are alive without progression post-AHSCT (at D þ 824, þ 1075, þ 1183, þ 1221 and þ 1638).
Non-Hodgkin lymphoma. Four NHL patients died before D þ 100 and were not evaluable for tumor response, although none had evidence of progression. Of the 18 patients who survived to XD þ 100, nine of those 16 (ie 56%) not in second CR at the time of AHSCT achieved CR. Three of these patients are currently alive and diseasefree at D þ 1075, þ 1183 and þ 1221.
Hodgkin lymphoma. All four patients are alive at the time of this report. However, one patient with primary refractory disease (ie oinitial PR) after ABVD achieved only PR by D þ 100 after HDMEL 280 mg/ m 2 þ AF þ AHSCT and was treated subsequently with local radiation at another institution in an attempt to produce CR. After a response, he recurred and received an allogeneic HSCT at D þ 469 and achieved CR but had progression at D þ 807. Another patient with HL refractory to induction therapy (ie oinitial PR) recently relapsed on D þ 411 and now is in CR at D þ 711 following local radiotherapy. Two patients were in second CR at the time of AHSCT and remain so at D þ 1638 and D þ 824.
Deaths in CR
Two NHL patients died while in CR post-AHSCT; one died due to P. carinii pneumonia on D þ 114 and the other of secondary MDS on D þ 1179.
Dose effect
Owing to the nature of this trial, it was not possible to ascertain a clear dose effect of the HDMEL doses utilized, that is, 220-300 mg/m 2 (see Table 3 ).
Overall and progression-free survival
As indicated in Figure 1 , median overall survival was D þ 286 (range D þ 9 to at least D þ 1638). As indicated in Figure 2 , median progression-free survival was also D þ 286 (range D þ 0 to at least D þ 1638).
Discussion
For both conventional-dose chemotherapy, 29 as well as HDC requiring AHSCT, 1-8 the vast majority of antilymphoma chemotherapy is administered in combination, mainly to address the issue of drug resistance. While usually appropriate, this may not be an optimal strategy in situations in which the dose of the most active agent is compromised in order to permit utilization of other, less active agents; this may be the case with myeloma treated with HDC and AHSCT. 30 Also, single-agent therapy with melphalan is simpler to administer, and may be less toxic to certain organs 15 and may be less costly. 31 That said, while it seems unlikely that single-agent chemotherapy, regardless of dose, will be suitable to eradicate resistant hematologic cancer, we are not advocating a switch to this strategy. Nonetheless, the activity of various elements of combinations is worth knowing.
HDMEL (usually B200 mg/m 2 ) þ AHSCT has been used extensively in myeloma, 32 and less so in Hodgkin disease 31 and the acute leukemias. 33 While the activity of HDMEL as a single agent in NHL is unclear -both in more conventional doses and those requiring AHSCT 12 -HDMEL is important as a component of several important antilymphoma regimens, as indicated by its use in 'BEAM', 9 and its use in the non-AHSCT regimen 'mini-BEAM' 34 suggests substantial activity. Accordingly, the data generated in our study were generally supportive of this postulate, although of course not definitive. Patients with refractory (ie 'chemoinsensitive') disease are the most stringent test of activity; in such patients with NHL, a D þ 100 CR rate of 50% was seen (ie four of eight were observed, and two of these patients remain in CR.) In those patients with refractory HL, the D þ 100 CR rate was also 50% (ie in one of two), although neither of these patients remains in CR. Again, and within the constraints of phase II trials, there is little to suggest this regimen is superior or inferior to multiagent therapies.
In contrast to NHL, there is somewhat more (although still quite limited) data on the use of HDMEL/AHSCT as a single agent in HL. 31, 35 Again, comparisons of phase II studies are problematic; HDMEL 200 mg/m 2 may not be an inferior regimen in terms of response to more conventional HDC regimens, and its use may be economically attractive. 31 Our findings are generally supportive; although only four HL patients were so treated, two remain in CR. Obviously, there are insufficient data in this report to suggest better results with higher doses.
Conversely, we recognize shortcomings with these data. First, the number of patients, especially in the various subgroups of lymphoma, is small -limiting confidence in any conclusions. Second, most patients were treated in the Phase I trial, and thus were not necessarily managed in the same way as more usual ASHCT protocol patients with these diseases, especially with respect to post-AHSCT therapy; clearly, these additional measures could have an influence on outcome.
Third, since some of these patients did not meet eligibility criteria for 'first-line' HDC/AHSCT regimens, they may not be representative of more usual patients with NHL or HL requiring HDC þ AHSCT. In addition, phase I patients were treated with variable HDMEL doses, producing additional heterogeneity. This is particularly problematic with the patients who received HDMEL 300 mg/m 2 , a dose deemed excessive in our phase I trial, 21 but which provided excellent outcomes in three of six cases reported herein. As indicated in this report, the failure to clearly define a DLT, plus the relatively uncomplicated nature of the other patients given MEL 300 mg/m 2 þ AF þ AHSCT, leads us to query whether MEL 280 mg/m 2 þ AF þ AHSCT is truly the MTD.
Finally, less likely but difficult to exclude is the possibility that the use of AF may have affected results, by any of several mechanisms. First, it could have provided antagonism to melphalan, by pharmacologic or by direct tumor protection. That said, we are unaware of data to support this contention, as certain clinical 36 and preclinical 20,37 data exist to suggest an absence of such an effect. Although ex vivo studies in acute myelogenous leukemia 38 suggest synergy with mafosfamide and possible intrinsic effects in the myelodysplastic syndromes; 39 we know of no such data in lymphoma. Thus, we believe the above data suggest minimal, if any, antitumor effect of AF in this setting.
Although we did not demonstrate a clear dose effect, it is worth noting that the lowest dose we administered, HDMEL 220 mg/m 2 , represents a 41.5-fold increase of HDMEL as used in BEAM. 9 Conversely, we are aware that some degree of dose attenuation may be required for safety reasons in the combination HDC (eg BEAM)/AHSCT setting.
Thus, we believe that these results, as well as the published data above, indicate that additional studies using HDC þ AF þ AHSCT in particular should be performed. While additional phase II studies with this single-agent regimen would be of interest in less-advanced cases, it seems unlikely that such will supplant combination therapy. More likely, these data could be used to justify the escalation of HDMEL þ AF þ AHSCT in existing regimens such as BEAM.
While it is beyond the scope of this manuscript to review the literature with respect to the use of AF in the case of HDC in the AHSCT setting, it is also appropriate to note that several studies have been published over the past few years. [40] [41] [42] [43] [44] [45] [46] These reports have been heterogeneous in design as well as patient-, disease-and treatment-related factors, and have, not surprisingly, had variable outcomes. That said, they are consistent with the hypothesis that AF provides useful cytoprotection in some circumstances.
Overall, this is one of a relatively small group of recent studies designed to produce better outcomes by dose intensification of current conditioning regimens. The most successful of these studies have been reported using radioimmunoconjugates to increase radiation doses without the anticipated damage to normal organs had external radiation been given in the form of TBI. 47 Although phase III studies have not been reported, improved results using this conjugate (and selected chemotherapy agents) vs TBI and these drugs in NHL have been reported. 48 However, these regimens are complicated to administer and do not lend themselves to widespread use-at least, not currently. If the use of cytoprotectants such as AF could permit safer use of simpler regimens, a wider overall benefit could be envisioned.
